Introduction
Angina pectoris results from reduced blood flow and oxygen supply to the heart muscle. Effective management of angina requires drugs that improve coronary blood flow, reduce cardiac workload, and enhance myocardial efficiency.
At Nirvana Pharma, we distribute a full range of anti-anginal medicines including nitrates, calcium channel blockers, beta-blockers, and newer adjunctive agents.
π Anti-Anginal Product Catalogue
Nitrates (Vasodilators)
| Drug Name |
Classification |
Common Strengths (Dosage Forms) |
Primary Uses |
| Nitroglycerin (GTN) |
Nitrate |
Sublingual tab: 0.3, 0.4, 0.6 mg; Spray: 0.4 mg/dose; Patch: 0.1β0.8 mg/hr; IV: 5 mg/mL |
Acute angina, prophylaxis |
| Isosorbide dinitrate (ISDN) |
Nitrate |
Tab: 5, 10, 20, 40 mg; SR: 40, 60 mg; Sublingual: 5 mg |
Chronic stable angina, CHF |
| Isosorbide mononitrate (ISMN) |
Nitrate |
Tab: 10, 20 mg; SR: 30, 60, 120 mg |
Chronic stable angina |
Calcium Channel Blockers (CCBs)
| Drug Name |
Classification |
Common Strengths (Dosage Forms) |
Primary Uses |
| Amlodipine |
DHP CCB |
Tab: 2.5, 5, 10 mg |
Angina, hypertension |
| Nifedipine |
DHP CCB |
Tab (IR/ER): 10, 20, 30, 60 mg |
Angina, hypertension |
| Felodipine |
DHP CCB |
ER tab: 2.5, 5, 10 mg |
Angina, hypertension |
| Verapamil |
Non-DHP CCB |
Tab: 40, 80, 120 mg; ER: 180, 240 mg |
Angina, arrhythmia |
| Diltiazem |
Non-DHP CCB |
Tab: 30, 60, 90 mg; ER: 120, 180, 240 mg |
Angina, arrhythmia |
Beta-Blockers
| Drug Name |
Classification |
Common Strengths (Dosage Forms) |
Primary Uses |
| Metoprolol tartrate |
Ξ²1-selective |
Tab: 25, 50, 100 mg |
Angina, arrhythmia, hypertension |
| Metoprolol succinate (ER) |
Ξ²1-selective |
ER tab: 25, 50, 100, 200 mg |
Angina, CHF |
| Atenolol |
Ξ²1-selective |
Tab: 25, 50, 100 mg |
Angina, hypertension |
| Bisoprolol |
Ξ²1-selective |
Tab: 2.5, 5, 10 mg |
Angina, CHF, hypertension |
| Propranolol |
Non-selective |
Tab: 10, 40, 80 mg; ER: 60, 120, 160 mg |
Angina, arrhythmia, migraine |
| Carvedilol |
Non-selective + Ξ±1 |
Tab: 3.125, 6.25, 12.5, 25 mg |
Angina, CHF |
Newer & Adjunctive Agents
| Drug Name |
Classification |
Common Strengths (Dosage Forms) |
Primary Uses |
| Ivabradine |
If-channel inhibitor |
Tab: 2.5, 5, 7.5 mg |
Chronic stable angina, CHF |
| Ranolazine |
Late NaβΊ current inhibitor |
ER tab: 500, 1000 mg |
Chronic stable angina (adjunct) |
| Trimetazidine |
Metabolic modulator |
Tab: 20 mg; MR: 35 mg |
Chronic stable angina (adjunct) |
| Nicorandil |
KβΊ channel opener + nitrate-like |
Tab: 5, 10, 20 mg |
Angina prophylaxis |
Closing Note
Our anti-anginal portfolio includes both first-line agents (nitrates, CCBs, beta-blockers) and modern adjuncts (Ivabradine, Ranolazine, Trimetazidine, Nicorandil), helping clinicians optimize therapy for acute and chronic angina patients. Nirvana Pharma ensures authentic sourcing, strict compliance, and reliable distribution for cardiovascular care.
